Compare GNS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | AYTU |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 27.4M |
| IPO Year | 2021 | 2015 |
| Metric | GNS | AYTU |
|---|---|---|
| Price | $0.14 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 5.0M | 47.5K |
| Earning Date | 09-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 136.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $127.02 | $17.96 |
| Revenue Next Year | $36.19 | $27.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.14 | $1.80 |
| 52 Week High | $1.06 | $3.07 |
| Indicator | GNS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 41.58 |
| Support Level | N/A | $2.05 |
| Resistance Level | $0.23 | $2.34 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.94 | 13.16 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.